ArticleVirology2010
An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120.
Article in Virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Peptides for Vaccine Development.ACS applied bio materials · 2022Review
- Peptides to combat viral infectious diseases.Peptides · 2020Review
- T = 4 Icosahedral HIV-1 Capsid As an Immunogenic Vector for HIV-1 V3 Loop Epitope Display.Viruses · 2018Article
- Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory.International journal of molecular sciences · 2016Review
- Article
- Identification of Peptide Mimics of a Glycan Epitope on the Surface of Parasitic Nematode Larvae.PloS one · 2016Article
- The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.The FEBS journal · 2015Article
- Antibody Binding Selectivity: Alternative Sets of Antigen Residues Entail High-Affinity Recognition.PloS one · 2015Article
- Protein engineering strategies for the development of viral vaccines and immunotherapeutics.FEBS letters · 2014Review
- Transplanting supersites of HIV-1 vulnerability.PloS one · 2014Article
- Synergism between a CD4-mimic peptide and antibodies elicited by a constrained V3 peptide.AIDS research and human retroviruses · 2013Article
- Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology.Journal of peptide science : an official publication of the European Peptide Society · 2013Review
- Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.Virology journal · 2012Article
- Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.Vaccine · 2012Article
- Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals.Virology · 2012Article
- Basic research in HIV vaccinology is hampered by reductionist thinking.Frontiers in immunology · 2012Article
- Structure-based design of a protein immunogen that displays an HIV-1 gp41 neutralizing epitope.Journal of molecular biology · 2011Article
- Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.Journal of virology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Synthetic peptides offer an attractive option for development of a V3-directed vaccine. However, immunization with flexible linear peptides may result in an immune response to multiple conformations, many of which differ from the native conformation of the corresponding region in the protein. Here we show that optimization of the location of a disulfide bond in peptides constrained to mimic the beta-hairpin conformation of the V3, yields an immunogen that elicits a 30-fold stronger HIV-1 neutralizing response in rabbits compared with the homologous linear V3 peptide. The HIV-1 neutralizing response elicited by the optimally constrained peptide is also significantly stronger than that elicited by a gp120 construct in which the V3 is exposed. Neutralization of an HIV-1 strain that shares only 72% identity with the immunizing peptide was demonstrated. The most effective immunogen was also able to neutralize primary isolates that are more resistant to neutralization such as SS1196 and 6535.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.